Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target

Wedbush analyst Yun Zhong has reiterated an 'Outperform' rating on Rocket Pharmaceuticals (NASDAQ: RCKT) and maintained a price target of $15 for the stock. This indicates a positive outlook for the company's performance in the market.